Get the Stockscreener App
38.38
6.31%
-2.48
Mineralys Therapeutics Inc stock is traded at $38.38, with a volume of 319.61K.
It is down -6.31% in the last 24 hours and up +0.58% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$40.86
Open:
$39.84
24h Volume:
319.61K
Relative Volume:
0.20
Market Cap:
$2.55B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-14.06
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
-5.62%
1M Performance:
+0.58%
6M Performance:
+148.25%
1Y Performance:
+184.61%
1-Day Range:
$38.02
$42.00
1-Week Range:
$38.02
$43.43
52-Week Range:
$8.241
$44.80
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
38.39 | 3.17B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.97 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
632.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.67 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.64 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.94 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Will Mineralys Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trading Summary & Fast Gaining Stock Reports - newser.com
Mineralys Therapeutics (NASDAQ: MLYS) sets Q3 results call for 4:30 p.m. ET - Stock Titan
Price action breakdown for Mineralys Therapeutics Inc.Weekly Volume Report & Weekly Breakout Opportunity Watchlist - newser.com
Multi factor analysis applied to Mineralys Therapeutics Inc.July 2025 Summary & Real-Time Market Sentiment Reports - newser.com
Can Mineralys Therapeutics Inc. hit a new high this monthForecast Cut & Low Drawdown Momentum Trade Ideas - newser.com
How Mineralys Therapeutics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Heatmap analysis for Mineralys Therapeutics Inc. and competitorsWeekly Market Outlook & Weekly Market Pulse Updates - newser.com
Mineralys Therapeutics Inc. stock trendline breakdownJuly 2025 Patterns & Real-Time Volume Trigger Notifications - newser.com
Jennison Associates LLC Sells 743,711 Shares of Mineralys Therapeutics, Inc. $MLYS - MarketBeat
What moving averages say about Mineralys Therapeutics Inc.2025 Market Trends & Verified Trade Idea Suggestions - newser.com
Why Mineralys Therapeutics Inc. stock is favored by top institutionsWatch List & Real-Time Buy Signal Alerts - newser.com
Is Mineralys Therapeutics Inc. stock a dividend growth opportunity2025 Technical Patterns & High Accuracy Swing Entry Alerts - newser.com
Real time scanner hits for Mineralys Therapeutics Inc. explained2025 Year in Review & Real-Time Buy Zone Alerts - newser.com
Has Mineralys Therapeutics Inc. found a price floorQuarterly Earnings Summary & Short-Term High Return Strategies - newser.com
Mineralys Therapeutics (NASDAQ:MLYS) Price Target Raised to $52.00 - MarketBeat
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC), Thermo Fisher (TMO) and Mineralys Therapeutics, Inc. (MLYS) - The Globe and Mail
Will Mineralys Therapeutics Inc. stock maintain growth storyBuy Signal & Community Verified Trade Alerts - newser.com
Mineralys Therapeutics to Present Key Lorundrostat Data at ASN Kidney Week 2025 - MSN
Is Mineralys Therapeutics Inc a good long term investmentMarket Breadth Indicators & Free High Velocity Capital Growth - earlytimes.in
Ranking Mineralys Therapeutics Inc. among high performing stocks via toolsMarket Trend Review & Verified Technical Signals - newser.com
Can machine learning forecast Mineralys Therapeutics Inc. recoveryQuarterly Trade Review & Capital Efficient Trade Techniques - newser.com
Mineralys Therapeutics prices upsized $250M stock offering - MSN
Why Mineralys Therapeutics Stock is Climbing Higher - TipRanks
Mineralys Therapeutics price target raised to $52 from $42 at H.C. Wainwright - TipRanks
HC Wainwright & Co. Maintains Mineralys Therapeutics (MLYS) Buy Recommendation - Nasdaq
Momentum divergence signals in Mineralys Therapeutics Inc. chartWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Mineralys Therapeutics Inc. stock recession proofJuly 2025 Opening Moves & Real-Time Market Sentiment Alerts - newser.com
12,300 Shares in Mineralys Therapeutics, Inc. $MLYS Bought by Allianz Asset Management GmbH - MarketBeat
Is Mineralys Therapeutics Inc. stock a buy in volatile markets2025 Trading Volume Trends & Fast Entry High Yield Tips - Fundação Cultural do Pará
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):